ReviewCurrent opinion in nephrology and hypertension2019
Thyroid disease in end-stage renal disease.
Review in Current opinion in nephrology and hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Thyroid function, nutritional status, inflammation, and sarcopenia in hemodialysis patients: an integrated cross-sectional analysis.Endocrine connections · 2026Article
- Article
- Kidney diseases and the thyroid: interactions and consequences.Nature reviews. Endocrinology · 2026Review
- Endocrine disorders linked to chronic kidney disease: Mechanisms and clinical implications.World journal of nephrology · 2026Review
- Low fT3 Syndrome, Dialysis Inadequacy, and Death Occurrence in Hemodialysis Patients: Evidence of a Vicious Circle from a Prospective Bi-Center Observational Study.Journal of clinical medicine · 2026Article
- The effect of thyroid disorders on the cutaneous manifestations in patients with chronic kidney disease.Renal failure · 2025Review
- The Correlation Between Impaired Thyroid Hormone Sensitivity and Diabetic Nephropathy in Euthyroid Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Thyroid Dysfunction in Patients With End-Stage Renal Disease: A Single-Centered Experience From Pakistan.Cureus · 2025Article
- Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies.Journal of clinical medicine · 2024Article
- Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease.Cureus · 2024Article
- Cross-section of thyroidology and nephrology: Literature review and key points for clinicians.Journal of clinical & translational endocrinology · 2024Review
- [Pituitary disorders in patients with end-stage chronic renal failure].Problemy endokrinologii · 2024Article
- Machine learning assessment of vildagliptin and linagliptin effectiveness in type 2 diabetes: Predictors of glycemic control.PloS one · 2024Article
- Thyroid, Gonadal and Adrenal Dysfunction in Kidney Transplant Recipients: A Review for the Clinician.Biomolecules · 2023Review
- Choosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologist.Journal of nephrology · 2023Review
- Kidney disease and thyroid dysfunction: the chicken or egg problem.Pediatric nephrology (Berlin, Germany) · 2022Review
- Two Cases of Autoimmune Thyroid Disorders after COVID Vaccination in Dialysis Patients.International journal of molecular sciences · 2022Article
- Elevated serum thyrotropin levels and endothelial dysfunction in a prospective hemodialysis cohort.Hemodialysis international. International Symposium on Home Hemodialysis · 2022Article
- Serum Thyrotropin Elevation and Coronary Artery Calcification in Hemodialysis Patients.Cardiorenal medicine · 2022Article
- Thyroid Feedback Quantile-based Index correlates strongly to renal function in euthyroid individuals.Annals of medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewHypothyroidism is a highly prevalent endocrine disorder in the end-stage renal disease (ESRD) population, yet many cases may remain latent and undiagnosed. RECENT
findingsEpidemiologic data show that there is a nearly five-fold higher prevalence of hypothyroidism in advanced chronic kidney disease (CKD) patients vs. those without CKD. Given that the metabolism, degradation, and excretion of thyroid hormone and its metabolites, as well as the regulation of the hypothalamic-pituitary-thyroid axis may be altered in ESRD, certain considerations should be made when interpreting thyroid functional tests in these patients. Growing evidence shows that hypothyroidism and other thyroid functional test derangements are associated with higher risk of cardiovascular disease, worse patient-centered outcomes, and survival in the advanced CKD population, including those with ESRD. Although limited data examining treatment of hypothyroidism suggests benefit, further studies of the efficacy and safety of thyroid hormone supplementation, including clinical trials and rigorous longitudinal observational studies are needed to inform the management of thyroid dysfunction in CKD. SUMMARY: Given the high burden of hypothyroidism in ESRD patients, and potential ill effects on their cardiovascular health, patient-centered outcomes, and survival, further research is needed to inform the optimal management of thyroid dysfunction in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.